A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G)
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs ACH 4471 (Primary)
- Indications Glomerulonephritis; Membranoproliferative glomerulonephritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 12 Mar 2018 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.
- 12 Mar 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Aug 2019.
- 12 Mar 2018 Status changed from not yet recruiting to recruiting.